全文获取类型
收费全文 | 3745篇 |
免费 | 296篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 83篇 |
妇产科学 | 43篇 |
基础医学 | 485篇 |
口腔科学 | 142篇 |
临床医学 | 466篇 |
内科学 | 624篇 |
皮肤病学 | 67篇 |
神经病学 | 286篇 |
特种医学 | 149篇 |
外科学 | 623篇 |
综合类 | 56篇 |
预防医学 | 353篇 |
眼科学 | 124篇 |
药学 | 226篇 |
中国医学 | 5篇 |
肿瘤学 | 274篇 |
出版年
2023年 | 25篇 |
2022年 | 34篇 |
2021年 | 107篇 |
2020年 | 48篇 |
2019年 | 96篇 |
2018年 | 115篇 |
2017年 | 84篇 |
2016年 | 86篇 |
2015年 | 78篇 |
2014年 | 147篇 |
2013年 | 221篇 |
2012年 | 278篇 |
2011年 | 314篇 |
2010年 | 197篇 |
2009年 | 145篇 |
2008年 | 279篇 |
2007年 | 250篇 |
2006年 | 244篇 |
2005年 | 259篇 |
2004年 | 227篇 |
2003年 | 210篇 |
2002年 | 197篇 |
2001年 | 24篇 |
2000年 | 11篇 |
1999年 | 24篇 |
1998年 | 32篇 |
1997年 | 22篇 |
1996年 | 17篇 |
1995年 | 11篇 |
1994年 | 19篇 |
1993年 | 17篇 |
1992年 | 12篇 |
1991年 | 12篇 |
1990年 | 16篇 |
1989年 | 12篇 |
1988年 | 8篇 |
1987年 | 15篇 |
1986年 | 6篇 |
1985年 | 11篇 |
1984年 | 13篇 |
1982年 | 9篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1977年 | 8篇 |
1975年 | 8篇 |
1974年 | 9篇 |
1973年 | 8篇 |
1971年 | 6篇 |
1970年 | 11篇 |
1969年 | 9篇 |
排序方式: 共有4053条查询结果,搜索用时 15 毫秒
81.
82.
Mauro Castellarin Katy Milne Thomas Zeng Kane Tse Michael Mayo Yongjun Zhao John R Webb Peter H Watson Brad H Nelson Robert A Holt 《The Journal of pathology》2013,229(4):515-524
High‐grade serous carcinoma (HGSC) is the most common and fatal form of ovarian cancer. While most tumours are highly sensitive to cytoreductive surgery and platinum‐ and taxane‐based chemotherapy, the majority of patients experience recurrence of treatment‐resistant tumours. The clonal origin and mutational adaptations associated with recurrent disease are poorly understood. We performed whole exome sequencing on tumour cells harvested from ascites at three time points (primary, first recurrence, and second recurrence) for three HGSC patients receiving standard treatment. Somatic point mutations and small insertions and deletions were identified by comparison to constitutional DNA. The clonal structure and evolution of tumours were inferred from patterns of mutant allele frequencies. TP53 mutations were predominant in all patients at all time points, consistent with the known founder role of this gene. Tumours from all three patients also harboured mutations associated with cell cycle checkpoint function and Golgi vesicle trafficking. There was convergence of germline and somatic variants within the DNA repair, ECM, cell cycle control, and Golgi vesicle pathways. The vast majority of somatic variants found in recurrent tumours were present in primary tumours. Our findings highlight both known and novel pathways that are commonly mutated in HGSC. Moreover, they provide the first evidence at single nucleotide resolution that recurrent HGSC arises from multiple clones present in the primary tumour with negligible accumulation of new mutations during standard treatment. 相似文献
83.
Wojciech Jurczak Simon Rule Peter Martin Rebecca Auer Brad S. Kahl Agnieszka Giza Bożena Jachimczak Ranjana H. Advani Jorge Romaguera Michael Williams Jacqueline Barrientos Ewa Chmielowska John Radford Stephan Stilgenbauer Jesse McGreivy Fong Clow Darrin M. Beaupre Lori Kunkel Michael L. Wang 《Acta haematologica Polonica》2013,44(3):314-318
Bruton's tyrosine kinase (BTK) is a central mediator of B-cell receptor (BCR) signaling essential for normal B-cell development. Ibrutinib is an oral BTK inhibitor that induces apoptosis and inhibits migration and adhesion of malignant B-cells. Updated results of this international, multicenter, phase 2 study of single agent ibrutinib in relapsed or refractory MCL will be presented.Ibrutinib 560 mg PO QD was administered continuously until disease progression. Tumor response was assessed every 2 cycles (one cycle = 28 days). The study enrolled 115 patients (65 bortezomib-naïve, 50 bortezomib-exposed); 111 patients were treated; 110 were evaluable for response. Baseline characteristics included: median age 68 years, time since diagnosis 42 months, number of prior treatments 3; bulky disease (>10 cm) 13%, prior stem cell transplant 10%, high risk MIPI 49%.Median time on treatment was 9.2 months; 53% of patients remain on therapy. Median PFS was 13.9 months and DOR has not yet been reached. Responses increased with longer treatment: comparing to previous data described at ASH 2011, the CR rate increased from 16% to 39%, and the ORR increased from 69% to 75%. 相似文献
84.
W.R. Wayne Martin MD Michael Miles MD Qiaonan Zhong MD Johanna Hartlein APRN Brad A. Racette MD Scott A. Norris MD Mwiza Ushe MD Baijayanta Maiti MD PhD Susan Criswell MD Albert A. Davis MD PhD Paul T. Kotzbauer MD PhD Nigel J. Cairns PhD Richard J. Perrin MD PhD Joel S. Perlmutter MD 《Movement disorders》2021,36(4):948-954
85.
86.
87.
88.
Alison M. Binder Scott P. Commins Michelle L. Altrich Tyler Wachs Brad J. Biggerstaff Charles B. Beard Lyle R. Petersen Gilbert J. Kersh Paige A. Armstrong 《Annals of allergy, asthma & immunology》2021,126(4):411-416.e1
BackgroundAlpha-gal syndrome (AGS) is an emerging immunoglobulin E (IgE)–mediated allergy to galactose-alpha-1,3-galactose (alpha-gal). The geographic distribution and burden of AGS in the United States are unknown.ObjectiveTo characterize alpha-gal IgE testing patterns and describe the trends and distribution from 2010 to 2018 in the United States.MethodsThis retrospective analysis included all persons tested for alpha-gal IgE antibodies by Viracor-IBT Laboratories (Lee’s Summit, Missouri), the primary site of testing in the United States. Data included age and sex of person tested, specimen state of origin, collection date, and result value; persons with at least 1 positive test result (≥0.1 kU/L) were compared with negatives. Proportions tested and with positive test results were calculated using the US Census population estimates.ResultsOverall, 122,068 specimens from 105,674 persons were tested for alpha-gal IgE during July 1, 2010, to December 31, 2018. Nearly one-third (34,256, 32.4%) had at least 1 positive result. The number of persons receiving positive test results increased 6-fold from 1110 in 2011 to 7798 in 2018. Of those receiving positive test results, mean [SD] age was 46.9 (19.8) years; men were more likely to test positive than women (43.3% vs 26.0%). Arkansas, Virginia, Kentucky, Oklahoma, and Missouri had the highest number of persons who were tested and had a positive result per 100,000 population.ConclusionMore than 34,000 persons, most presumably symptomatic, have received positive test results for IgE antibodies to alpha-gal, suggesting AGS is an increasingly recognized public health problem. The geographic distribution of persons who tested positive is consistent with exposure to Amblyomma americanum ticks. 相似文献
89.
Allison J. Armstrong Maria Sol Collado Brad R. Henke Matthew W. Olson Stephen A. Hoang Christin A. Hamilton Taylor D. Pourtaheri Kimberly A. Chapman Marshall M. Summar Brian A. Johns Brian R. Wamhoff John E. Reardon Robert A. Figler 《Molecular genetics and metabolism》2021,132(1):71-82
Propionic Acidemia (PA) and Methylmalonic Acidemia (MMA) are inborn errors of metabolism affecting the catabolism of valine, isoleucine, methionine, threonine and odd-chain fatty acids. These are multi-organ disorders caused by the enzymatic deficiency of propionyl-CoA carboxylase (PCC) or methylmalonyl-CoA mutase (MUT), resulting in the accumulation of propionyl-coenzyme A (P-CoA) and methylmalonyl-CoA (M-CoA in MMA only). Primary metabolites of these CoA esters include 2-methylcitric acid (MCA), propionyl-carnitine (C3), and 3-hydroxypropionic acid, which are detectable in both PA and MMA, and methylmalonic acid, which is detectable in MMA patients only (Chapman et al., 2012). We deployed liver cell-based models that utilized PA and MMA patient-derived primary hepatocytes to validate a small molecule therapy for PA and MMA patients. The small molecule, HST5040, resulted in a dose-dependent reduction in the levels of P-CoA, M-CoA (in MMA) and the disease-relevant biomarkers C3, MCA, and methylmalonic acid (in MMA). A putative working model of how HST5040 reduces the P-CoA and its derived metabolites involves the conversion of HST5040 to HST5040-CoA driving the redistribution of free and conjugated CoA pools, resulting in the differential reduction of the aberrantly high P-CoA and M-CoA. The reduction of P-CoA and M-CoA, either by slowing production (due to increased demands on the free CoA (CoASH) pool) or enhancing clearance (to replenish the CoASH pool), results in a net decrease in the CoA-derived metabolites (C3, MCA and MMA (MMA only)). A Phase 2 study in PA and MMA patients will be initiated in the United States. 相似文献